Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Rosuvastatin · DIN 02405652 Manufacturer: Sanis Health Inc.; listing date 2016-05-31 Health Canada: Marketed since 2022-09-01 · brand ROSUVASTATIN · ATC C10AA07 ROSUVASTATIN · form Tablet · route Oral · ingredients ROSUVASTATIN (ROSUVASTATIN CALCIUM) 40 MG · company Sanis health inc · schedule Prescription

DIN 02405652: Rosuvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600048; group id 308; item number 0677; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1990; ministry $0.1990 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405652 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89042

Interchangeable products

Ach-Rosuvastatin · DIN 02438941 · $0.1990 Apo-Rosuvastatin · DIN 02338009 · $0.1990 Auro-Rosuvastatin · DIN 02442604 · $0.1990 Co Rosuvastatin · DIN 02339803 · $0.1990 Crestor · DIN 02247164 · $0.1990 Jamp Rosuvastatin Calcium · DIN 02498367 · $0.1990 Jamp-Rosuvastatin · DIN 02391287 · $0.1990 M-Rosuvastatin · DIN 02496569 · $0.1990 Mar-Rosuvastatin · DIN 02413108 · $0.1990 Med-Rosuvastatin · DIN 02399199 · $0.1990 Mint-Rosuvastatin · DIN 02397838 · $0.1990 NRA-Rosuvastatin · DIN 02477513 · $0.1990 NRA-Rosuvastatin Tablets · DIN 02536633 · $0.1990 PMS-Rosuvastatin · DIN 02378566 · $0.1990 PRZ-Rosuvastatin · DIN 02505606 · $0.1990 Rosuvastatin · DIN 02411652 · $0.1990 Sandoz Rosuvastatin · DIN 02338750 · $0.1990 Taro-Rosuvastatin · DIN 02382679 · $0.1990 Teva-Rosuvastatin · DIN 02354632 · $0.1990

Shortage status: resolved shortage (ended 2025-12-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02405652

Shortage record checked 2026-09-13T08:10:21.292534+00:00